Stuart Therapeutics Entered into an Exclusive License Agreement with Glaukos Corporation to Develop the First Neuroprotective Therapy
Shots:
- Stuart will receive an up front & is eligible for additional development & sales-related milestones along with royalties. Glaukos will assume all costs for the development of ST-113
- Glaukos gets an exclusive right globally to develop & commercialize Stuart's ST-113 for neuroprotection in glaucoma. In animal studies, the patented pre-clinical asset ST-113 showed the capacity to provide neuroprotection & neuro-repair of optic nerve axons
- ST-113 is being investigated as a treatment for open-angle glaucoma, incl. normal tension glaucoma. The therapy helps restore the structural & cell signaling roles of collagen in the optic nerve region, reducing inflammation, and restoring nerve health acc. to preclinical research results
Ref: PR Newswire | Image: Glaukos
Related News:- iVeena Entered into a License Agreement with Glaukos to Develop and Commercialize IVMED-80 for keratoconus
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
